Presant C A, Kennedy P S, Wiseman C, Gala K, Bouzaglou A, Wyres M, Naessig V
Am J Clin Oncol. 1986 Aug;9(4):355-7. doi: 10.1097/00000421-198608000-00016.
A pilot study of the use of verapamil and adriamycin in patients with advanced malignancy was conducted to determine if the two drugs could be safely combined and to explore whether antitumor responses were frequent. The dosage of adriamycin was 50 mg/M2 every 3 weeks. Eight doses of verapamil were given orally every 6 hours, with adriamycin being administered after the fourth dose. In five patients 240 mg of verapamil taken every 6 hours produced unacceptable nausea, vomiting, hypotension, and arrhythmia. In eight patients, 120 mg of verapamil taken every 6 hours was tolerated moderately well. In four adriamycin-resistant patients, the combination of adriamycin and verapamil produced one partial response and two minor regressions. Further studies using this combination are warranted.
开展了一项关于维拉帕米和阿霉素用于晚期恶性肿瘤患者的初步研究，以确定这两种药物能否安全联用，并探究抗肿瘤反应是否常见。阿霉素的剂量为每3周50mg/M²。维拉帕米每6小时口服8剂，在第4剂后给予阿霉素。5例患者每6小时服用240mg维拉帕米出现了难以接受的恶心、呕吐、低血压和心律失常。8例患者每6小时服用120mg维拉帕米耐受性尚可。在4例对阿霉素耐药的患者中，阿霉素与维拉帕米联用产生了1例部分缓解和2例轻度消退。有必要对这种联合用药进行进一步研究。
